Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2025-05-20 9:02 pm Purchase | 2025-05-13 | 13G | CytomX Therapeutics, Inc. CTMX | Seven Fleet Partners LP | 377,161 0.200% | 377,161![]() (New Position) | Filing History |
2025-05-20 9:00 pm Purchase | 2025-05-13 | 13G | CytomX Therapeutics, Inc. CTMX | Longitude Capital Partners V, LLC | 11,538,461 7.300% | 11,538,461![]() (New Position) | Filing History |
2025-05-20 4:25 pm Purchase | 2025-05-13 | 13G | CytomX Therapeutics, Inc. CTMX | Venrock Healthcare Capital Partners III, L.P. | 12,992,500 8.200% | 12,992,500![]() (New Position) | Filing History |
2025-05-15 4:15 pm Sale | 2025-03-31 | 13G | CytomX Therapeutics, Inc. CTMX | TANG CAPITAL MANAGEMENT, LLC | 6,717,825 8.400% | -1,093,935![]() (-14.00%) | Filing History |
2025-05-14 5:14 pm Purchase | 2025-05-12 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 13,094,400 8.300% | 13,094,400![]() (New Position) | Filing History |
2025-02-14 11:34 am Sale | 2024-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | JANUS HENDERSON GROUP PLC JHG | 0 0.000% | -4,809,518![]() (Position Closed) | Filing History |
2024-11-14 4:26 pm Purchase | 2024-09-30 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 8,089,795 9.990% | 1,386,906![]() (+20.69%) | Filing History |
2024-11-14 4:00 pm Purchase | 2024-09-30 | 13G | CytomX Therapeutics, Inc. CTMX | TANG CAPITAL MANAGEMENT, LLC | 7,811,760 9.990% | 7,811,760![]() (New Position) | Filing History |
2024-11-14 3:03 pm Sale | 2024-09-30 | 13G | CytomX Therapeutics, Inc. CTMX | Cormorant Asset Management LP | 0 0.000% | -5,750,000![]() (Position Closed) | Filing History |
2024-11-14 12:28 pm Purchase | 2024-09-30 | 13G | CytomX Therapeutics, Inc. CTMX | JANUS HENDERSON GROUP PLC JHG | 4,809,518 6.200% | 651,408![]() (+15.67%) | Filing History |
2024-05-22 4:06 pm Purchase | 2024-05-13 | 13G | CytomX Therapeutics, Inc. CTMX | JANUS HENDERSON GROUP PLC JHG | 4,158,110 5.300% | 4,158,110![]() (New Position) | Filing History |
2024-05-13 4:00 pm Purchase | 2024-05-02 | 13G | CytomX Therapeutics, Inc. CTMX | Cormorant Asset Management LP | 5,750,000 7.380% | 5,750,000![]() (New Position) | Filing History |
2024-02-14 4:00 pm Purchase | 2023-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | TANG CAPITAL PARTNERS LP | 6,550,000 9.800% | 3,039,555![]() (+86.59%) | Filing History |
2024-02-14 10:09 am Purchase | 2023-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 6,702,889 9.990% | 107,088![]() (+1.62%) | Filing History |
2024-02-13 5:02 pm Purchase | 2023-12-29 | 13G | CytomX Therapeutics, Inc. CTMX | The Vanguard Group | 4,902,943 7.320% | 317,222![]() (+6.92%) | Filing History |
2023-02-14 4:13 pm Sale | 2022-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 0 0.000% | -6,312,371![]() (Position Closed) | Filing History |
2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | TANG CAPITAL PARTNERS LP | 3,510,445 5.300% | 39,545![]() (+1.14%) | Filing History |
2023-02-14 10:22 am Sale | 2022-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | RTW Investments, LP | 0 0.000% | -6,029,700![]() (Position Closed) | Filing History |
2023-02-09 11:16 am Sale | 2022-12-30 | 13G | CytomX Therapeutics, Inc. CTMX | The Vanguard Group | 4,585,721 6.940% | -522,270![]() (-10.22%) | Filing History |
2022-07-29 4:37 pm Purchase | 2022-07-27 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 6,595,801 10.100% | 792,101![]() (+13.65%) | Filing History |